Search results
15 gru 2020 · In this Review, we update our understanding of B cell biology, review the results of clinical trials using BCDT in autoimmune indications, discuss hypotheses for the mechanism of action of BCDT...
- Full Size Table
Full Size Table - B cell depletion therapies in autoimmune...
- Full Size Image
Full Size Image - B cell depletion therapies in autoimmune...
- Metrics
Metrics - B cell depletion therapies in autoimmune disease:...
- Full Size Table
3 dni temu · On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy.
15 lis 2022 · Axi-cel is a safe first-line treatment for adult patients with high-risk LBCL, including those with positive interim PET2 and either DHL/THL lymphomas or an IPI score of 3-5. The efficacy and outcomes can be improved by incorporating CAR-T cell therapy into managing double-hit and triple-hit diffuse large B-cell lymphoma who are PET-2 positive.
In this review, we focus on recent clinical and mechanistic insights into the efficacy of B cell depletion in these diverse autoimmune disorders, the rapidly expanding armamentarium of approved agents, and future approaches.
4 sty 2024 · The introduction of rituximab―a monoclonal antibody that targets the CD20 antigen on B-cells―in the early 2000s revolutionized DLBCL treatment, substantially enhancing survival outcomes...
24 wrz 2024 · In this review, we summarize the main ongoing frontline randomized trials and discuss some of the questions that we will face in interpreting and applying their results in clinical practice in the next few years.
15 lis 2022 · Inpatient costs represented the highest percentage of total costs, followed by outpatient costs. New 1L treatments that are both efficacious and cost-effective in DLBCL are needed to reduce the economic burden to the healthcare system in the R/R DLBCL setting.
